Ignite Creation Date:
2025-12-25 @ 5:06 AM
Ignite Modification Date:
2025-12-26 @ 4:09 AM
Study NCT ID:
NCT02390427
Status:
COMPLETED
Last Update Posted:
2024-10-02
First Post:
2015-03-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Sponsor:
Otto Metzger, MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04-20
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-07
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-11
First Submit QC Date:
None
Study First Post Date:
2015-03-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-01
Last Update Post Date:
2024-10-02
Last Update Post Date Type:
ACTUAL